Clinical Trial

Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV

Study acronym: SWIFT
Recruiting
View on ClinicalTrials.gov →
Summary
The prevalence of obesity is rising worldwide, both in low- and high-income countries, including people with HIV (PWH). Semaglutide's efficacy in achieving weight loss in obese PWH is still unexplored. The aim of this study is to assess the efficacy and safety of semaglutide in achieving greater weight loss compared to diet and excercise alone in obese PWH and to explore the effect of semaglutide on the immune function, markers of immune activation, viral reservoir, markers of glucose and lipid metabolism and gut microbiome.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2019-11-20; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Recruiting 2022-07-04
Trial Details
NCT Number NCT04174755
Lead Sponsor University College Dublin
Collaborators: University of Copenhagen, Rush University Medical Center
Conditions Obesity, HIV-1-infection
Enrollment 80 participants
Start Date 2022-06-22
Primary Completion 2027-01 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-29